A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).Corey J. Langer, M. S. Berger, Gábor Pajkos et al.|Journal of Clinical Oncology|2011Cited by 19
Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC).Alberto Chiappori, M. S. Berger, Marshall T. Schreeder et al.|Journal of Clinical Oncology|2010Cited by 3